<DOC>
	<DOCNO>NCT00170183</DOCNO>
	<brief_summary>Patients hospitalize treatment decompensated heart failure ( CHF ) risk prolong length stay ( LOS ) frequent readmission . Renal dysfunction diuretic resistance contribute risk , particularly renal dysfunction worsen CHF treatment . Brain natriuretic peptide ( BNP ) hormone myocardial cell origin well-defined physiological effect include arterial venous vasodilation , suppression adverse neurohumoral system favorable effect renal hemodynamics sodium excretion . Recombinant human BNP ( Natrecor ) approve FDA treatment decompensated CHF demonstrate low filling pressure improve symptom . While clinical trial FDA support use BNP adjuvant therapy decompensated CHF , extent efficacy improve non-hemodynamic CHF parameter fully define . The objective clinical practice protocol determine whether use BNP addition standard therapy , preserve renal function facilitate diuresis patient CHF mild-moderate renal impairment ( creatinine clearance &gt; 20 &lt; 60 ml/min ) compare standard therapy alone . Patients admit Mayo Heart Failure Service meet entrance criterion randomize standard clinical practice without 48 hour infusion BNP . The primary endpoint indices renal function diuretic response 1 , 2 3 day discharge . Secondary endpoint neurohumoral function , LOS 30-day readmission rate .</brief_summary>
	<brief_title>Brain Natriuretic Peptide ( BNP ) Preserve Renal Function Hospitalized Patients With Heart Failure</brief_title>
	<detailed_description>Hypothesis : The objective clinical practice protocol determine whether use BNP addition standard therapy , preserve renal function facilitate diuresis patient CHF renal impairment compare standard therapy alone . The study target patient mild moderate renal dysfunction adequate blood pressure require inotropic therapy felt need intravenous vasodilator therapy acute symptom control . Patients randomized admission heart failure service prior initiation therapy . Patients receive initial therapy emergency department eligible therapy give emergency department record . Inclusion criterion : - Clinical diagnosis class III-IV CHF require hospitalization treatment CHF . - Mild - moderate renal insufficiency ( 20 &lt; Creatinine Clearance &lt; 60 ml/min calculate Cockcroft-Gault formula ) - Systolic BP &gt; 90 - Stable cardiac rhythm - Unlikely require cardiac catheterization Exclusion criterion : - Inability give inform consent - New onset atrial fibrillation rapid ventricular response ( HR &gt; 110 bpm ) - Active ischemia - Known suspected stenotic valve disease - Acute clinical need intravenous vasodilator ( include BNP ) therapy ( Severely symptomatic despite rest , oxygen , initial standard therapy ) - Primary reason admission treatment decompensated CHF ( rhythm , device , medical problem ) Primary Endpoints : 1 . Creatinine , Creatinine Clearance 1,2,3 day discharge 2 . Wt loss 1,2,3 day discharge 3 . Fluid balance 1,2,3 day discharge 4 . Use advance therapy diuretic resistance ( inotropes , renal dopamine , ultrafiltration , dialysis ) 5 . Meets criteria diuretic resistance define standardize diuretic protocol Secondary Endpoints : 1 . LOS 2 . 30 day readmission CHF ( hospital record Â¡V Mayo patient phone call 30 day ) 3 . Plasma renin activity , aldosterone , ANP , BNP , N-proBNP , Angiotensin II , cGMP , ET , Cystatin C baseline prior end BNP infusion ( BNP group ) 48 hour entry ( standard care group ) . Cockcroft-Gault Formula ( Weight Kg ; Creatinine mg/dL - Use estimate Dry Weight ) Men Crt Cl = ( ( 140-Age ) *Weight ) / ( 72*Crt ) Women Crt Cl = 0.85 * ( ( 140-Age ) *Weight ) / ( 72*Crt ) Power calculation/Sample size : We tabulate HF hospital service profile regard renal function three-month period May-July 2002 140 patient admitted CHF service . Data calculate creatinine clearance available data base . Mild-moderate renal dysfunction characterize creatinine 1.4 - 3.0 mg/dL present 60 ( 43 % ) patient . This likely represent significant underestimation patient eligible study patient elderly creatinines &lt; 1.4 mg/dL often correlate creatinine clearance 20-60 range . In 60 patient creatinines 1.4-3.0 mg/dL , mean change creatinine hospitalization +0.022 + - 0.377 mg/dL . Using change expect standard therapy group , enrol 52 patient per treatment group ( n=104 total ) would provide 80 % power ( significance level 0.05 ) detect change 0.222 mg/dL mean creatinine ( + 0.022 -0.200 ) . Using creatinine , 0.222 mg/dL change represent effect size 0.58 . If one allocate representative weight age creatinines admission discharge calculates mean change creatinine clearance , value 1.54 + - 6.51 ml/min obtain . In case , difference 5 ml/min mean change creatinine clearance standard therapy treat group would represent somewhat high treatment effect ( 0.768 ) indicate adequate power detect difference 5 ml/min mean change creatinine clearance two group . Randomization : Patients randomize 1:1 standard therapy BNP + standard therapy . Randomization stratify creatinine clearance two group ( 20-39 ml/min 40-59 ml/min ) . Analysis : Primary endpoint : Mean change creatinine , creatinine clearance , fluid balance , body weight calculated 1 , 2 , 3 day discharge compare BNP standard therapy group . Percent patient meet criterion diuretic resistance percent patient receive advanced therapy diuretic resistance two group compare . All data analyze intention treat receive active therapy full 48 hour . Secondary endpoint : Mean length stay readmission rate compare two group . Differences group compare Students unpaired test continuous variable Fischers exact test nominal variable . Data entry duty nurse coordinator utilize paper electronic case report form currently use CV study unit . The Investigators utilize Center Patient Oriented Research consultation set analysis . Recruitment potential : &gt; 560 patients/year admit CHF service If 46 % crt creatinine clearance 20-59 ml/min = 257 patients/1 year If 50 % eligible patient enrol = 129 patients/1 year If 40 % eligible patient enrol = 103 patients/1 year If 30 % eligible patient enrol = 77 patients/1 year BNP therapy - treatment arm 2 ug/kg bolus 0.01 ug/kg/min x 48 hour long : Systolic BP ( SBP ) &gt; 90 symptom think relate decreased BP If SBP &lt; 90 asymptomatic- dc infusion , 250 cc NS , resume 0.007 ug/kg/min ( bolus ) BP &gt; 90 If SBP &lt; 90 symptomatic - dc infusion , 250 cc NS bolus , Trendlenberg , restart Standard therapy ( used arm ) : - ACE inhibitors/Angiotensin Receptor Blockers - initiate adjust per clinical judgement - Digoxin - per clinical judgement - Hydralazine/Isordil - per clinical judgement - Coumadin/Aspirin - per clinical judgement - Beta Blockers - per clinical judgement - Calcium channel blocker - per clinical judgement - Non-cardiac med - per clinical judgement - Spironolactone 1. already - continue current dose dc appropriate 2. already - increase dc clinically indicate 3. - add dc clinically indicate - Other diuretic - discontinue follow algorithm - Diet - 2 gm NaCl 1.5 Liter total fluid restriction - Daily weight ( scale ) - Accurate I O - Oxygen - per clinical judgement Diuretic therapy - Standardized Diuretic Algorithm base initial creatinine clearance ( see ) . BNP must start within 1-2 hour randomization Diuretics start 1 hour start BNP infusion BNP group . Diuretics start immediately randomization standard therapy group . The study period consider start initiation BNP ( BNP group ) diuretic ( Standard therapy group ) . Laboratory monitoring : Standard clinical care include daily electrolyte panel ( creatinine , blood urea nitrogen , sodium , potassium ) . Humoral function ( BNP , ANP , PRA , Aldosterone , ET , N-proBNP , Angiotensin II , cGMP ) baseline prior end Natrecor infusion ( research lab ) . Twenty ml blood standard EDTA tube five ml blood EDTA tube ACE inhibitor need per blood draw . Vitals monitoring : Standard clinical care include establish nursing protocol use BNP infusion telemetry . Introduction BNP clinical practice pilot CCU cardiology telemetry unit ( 4 Domatilla 4 Joesph ) CHF group standard clinical practice floor . Diuretic Algorithm : Initial dose subsequent dose diuretic follow diuretic algorithm outline . Can substitute bumex ( 1 mg bumex/ 40 mg furosemide ) . Can delay progression next level within 10 % goal fluid balance/weight . Clinician may use fluid balance OR weight make decision regard progression next level .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>Clinical diagnosis class IIIIV CHF require hospitalization treatment CHF . Mild moderate renal insufficiency ( 20 &lt; Creatinine Clearance &lt; 60 ml/min calculate CockcroftGault formula ) Systolic BP &gt; 90 Stable cardiac rhythm Unlikely require cardiac catheterization Inability give inform consent New onset atrial fibrillation rapid ventricular response ( HR &gt; 110 bpm ) Active ischemia Known suspect stenotic valve disease Acute clinical need intravenous vasodilator ( include BNP ) therapy ( Severely symptomatic despite rest , oxygen , initial standard therapy ) Primary reason admission treatment decompensated CHF ( rhythm , device , medical problem )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Renal dysfunction</keyword>
</DOC>